News

Fierce Pharma1d
Facing added pressure from Eli Lilly, Novo Nordisk submits for FDA approval of oral GLP-1 obesity drug
Nearly two years after reporting successful results from a phase 3 trial of its oral version of injected obesity treatment ...
Why Novo Nordisk Stock Popped Today
Novo Nordisk (NYSE: NVO), the Danish drugmaker that's been riding high ever since it began putting out Ozempic and Wegovy GLP ...
24/7 Wall St.2d
Novo Nordisk (NYSE: NVO) Stock Price Prediction and Forecast 2025-2030 (April 2025)
With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...
FDA stops sale of generic versions of Ozempic and Wegovy: What to do if you’re taking them
Many compounding pharmacies are no longer allowed to make cheaper versions of semaglutide and other GLP-1 drugs. A doctor ...
Novo Nordisk Investors Just Got Terrible News. Should You Sell the Stock?
Denmark-based pharmaceutical giant Novo Nordisk (NYSE: NVO) has been struggling during the past year. Its financial results - ...
Down 61%, Is Novo Nordisk Stock Worth Buying on the Dip?
Novo Nordisk remains an industry leader, and currently offers both a 2.7% dividend yield and compelling value that can work ...
FIRSTonline19h
Novo Nordisk Stumbles, Eli Lilly Launches Diabetes and Obesity Pill: Ready to Assault on Ozempic's Throne
Eli Lilly Takes on Novo Nordisk with Orforglipron, an Oral Drug for Diabetes and Obesity That Could Change the Market. FDA ...
Did Eli Lilly Just Say Checkmate to Novo Nordisk?
Novo Nordisk (NYSE: NVO) has seen revenue soar in recent years thanks to two drugs that have helped people around the world ...
The Local - Denmark1d
Denmark's Novo Nordisk sees shares tumble after competitor breakthrough
Shares in Danish drugmaker Novo Nordisk, maker of the blockbuster diabetes and weight-loss treatments Ozempic and Wegovy, ...
Novo Nordisk: Be Greedy When Others Are Fearful
Novo Nordisk's booming obesity drugs & diabetes portfolio make it a top growth play. Click here to read an analysis of NVO ...
Think It's Too Late to Buy Novo Nordisk? Here's the Biggest Reason Why There's Still Time.
Almost unarguably, the most significant story in our time with the pharmaceutical industry is the emergence and sharp rise of GLP-1 obesity drugs. Front and center of this is Novo Nordisk (NYSE: NVO), ...